|
|
 |
 |
| |
 Printable version |
Troxacitabine |
Bulletin du Cancer. Volume 91, Number 3, 213-8, Mars 2004, POINT SUR...
|
 Résumé
Article gratuit
|
Author(s) : Henriette Gourdeau, Jacques Jolivet |
Summary : Nucleoside analogues are commonly used in the treatment of hematological malignancies and solid tumors. As antimetabolites, these drugs act by disrupting DNA synthesis and inducing apoptosis following their incorporation into DNA. Troxacitabine (Troxatyl
TM) is the first nucleoside analogue with anticancer activity that has an unnatural stereochemical configuration. Its broad preclinical antineoplastic spectrum led to its clinical development. Summaries of the preclinical data and of the initial phase I and II clinical trials are presented. ▴ |
Keywords : troxacitabine, clinical treatment, solid tumor, hematological malignancy, chemotherapy |
|
